Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade (R)) to the biosimilar SB2 (Flixabi (R)) in inflammatory bowel disease patients - Fischer, Sven Moritz; Klenske, E.; Schmitt, H.; Vitali, Francesco; Hirschmann, S.; Koch, F.; Ramming, A.; Zundler, Sebastian; Nagore, D.; Uter, Wolfgang; Neurath, Markus; Atreya, Raja (2018)
EVALuna2:34075

CONFOCAL LASER ENDOMICROSCOPY CAN PREDICT MAJOR CLINICAL EVENTS WITH VERY HIGH SENSITIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES - Klenske, Entcho; Atreya, Raja; Zundler, Sebastian; Fischer, Sven Moritz; Neurath, Markus; Rath, Timo (GASTROINTESTINAL ENDOSCOPY, 2019)
CRIS-Team WoS Importer:2019-06-21

Luminal application of a GATA3-specific DNAzyme ameliorates mucosal inflammation in a randomised trial with active ulcerative colitis patients - Atreya, Raja; Kuehbacher, T.; Schmitt, H.; Hirschmann, S.; Waldner, Maximilian; Drvarov, O.; Fischer, Sven Moritz; Vetter, Marcel; Weigmann, Benno; Turowska, A.; Muhl, T.; Homburg, U.; et al. (2018)
EVALuna2:34074

Point of Care detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the biosimilar SB2: performance comparison with ELISA - Atreya, Raja; Schmitt, H.; Fischer, Sven Moritz; Neurath, Markus; Rekalde, X.; Nagore, D.; Ametzazurra, A. (JOURNAL OF CROHNS & COLITIS, 2019)
CRIS-Team WoS Importer:2019-03-20